vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and Rani Therapeutics Holdings, Inc. (RANI). Click either name above to swap in a different company.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing orally deliverable alternatives to injectable biologic therapies. Its core proprietary RaniPill technology is a robotic drug delivery capsule that administers large molecule drugs directly to the intestinal wall, eliminating the need for painful injections. The company serves patients with chronic conditions including diabetes, autoimmune disorders and osteoporosis, and collaborates with leading pharmaceutical partners to advance its product pipeline.
IVA vs RANI — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $0 |
| Net Profit | $-49.0M | $-5.4M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -961352.9% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | 20.2% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $172.0K | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $5.1K | $0 | ||
| Q1 24 | — | $0 |
| Q3 25 | — | $-5.4M | ||
| Q2 25 | — | $-6.7M | ||
| Q1 25 | — | $-7.3M | ||
| Q3 24 | — | $-6.8M | ||
| Q2 24 | $-49.0M | $-6.8M | ||
| Q1 24 | — | $-7.5M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6984.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4223.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | -961352.9% | — | ||
| Q1 24 | — | — |
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-0.18 | ||
| Q1 25 | — | $-0.22 | ||
| Q3 24 | — | $-0.24 | ||
| Q2 24 | — | $-0.26 | ||
| Q1 24 | — | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $4.1M |
| Total DebtLower is stronger | — | $13.8M |
| Stockholders' EquityBook value | $-85.4M | $-7.9M |
| Total Assets | $42.6M | $10.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.1M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $10.1M | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | $11.0M | $4.5M | ||
| Q1 24 | — | $6.9M |
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $21.3M | ||
| Q3 24 | — | $28.8M | ||
| Q2 24 | — | $30.0M | ||
| Q1 24 | — | $30.0M |
| Q3 25 | — | $-7.9M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | — | $-3.1M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | $-85.4M | $2.8M | ||
| Q1 24 | — | $7.4M |
| Q3 25 | — | $10.1M | ||
| Q2 25 | — | $16.9M | ||
| Q1 25 | — | $24.1M | ||
| Q3 24 | — | $43.5M | ||
| Q2 24 | $42.6M | $43.7M | ||
| Q1 24 | — | $53.5M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 9.21× | ||
| Q2 24 | — | 10.58× | ||
| Q1 24 | — | 4.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-5.1M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-8.1M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | — | $-9.0M | ||
| Q1 24 | — | $-9.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-8.2M | ||
| Q3 24 | — | $-8.5M | ||
| Q2 24 | — | $-9.1M | ||
| Q1 24 | — | $-9.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4767.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 29.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
